Drug Profile
TLC 388
Alternative Names: Lipotecan; TLC-388; TLC388 HClLatest Information Update: 04 May 2022
Price :
$50
*
At a glance
- Originator National Health Research Institutes; Taiwan Liposome Company
- Class Antineoplastics; Camptothecins
- Mechanism of Action Angiogenesis inhibitors; DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Liver cancer; Neuroendocrine tumours; Rectal cancer; Renal cell carcinoma; Solid tumours
Most Recent Events
- 26 Apr 2022 Discontinued - Phase-I for Solid tumours in USA (IV) (TLC pipeline, April 2022)
- 26 Apr 2022 Discontinued - Phase-II for Liver cancer (Late-stage disease, Second-line therapy or greater) in China (IV) (TLC pipeline, April 2022)
- 26 Apr 2022 Discontinued - Phase-II for Liver cancer (Late-stage disease, Second-line therapy or greater) in Taiwan (IV) (TLC pipeline, April 2022)